Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones

Weiss L. Comments on hematogenous metastatic patterns in humans as revealed by autopsy. Clin Exp Metastasis. 1992;10:191–9.

CAS  PubMed  Article  Google Scholar 

Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, et al. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. Prostate 2014;74:210–6.

PubMed  Article  Google Scholar 

Ashrafi AN, Fay C, Yip W, de Freitas DM, Nabhani J, Aron M. Durable biochemical response following adrenal metastasectomy for oligometastatic castrate-resistant prostate cancer. Urol Case Rep. 2020;32:101229.

PubMed  PubMed Central  Article  Google Scholar 

Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, et al. Rapid (“warm”) autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res. 2000;6:1038–45.

CAS  PubMed  Google Scholar 

Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006;66:2815–25.

CAS  PubMed  Article  Google Scholar 

Tamae D, Mostaghel E, Montgomery B, Nelson PS, Balk SP, Kantoff PW, et al. The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high-risk localized and advanced castration-resistant prostate cancer. Chem-Biol Interact. 2015;234:332–8.

CAS  PubMed  Article  Google Scholar 

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl J Med. 2011;364:1995–2005.

PubMed  PubMed Central  Article  Google Scholar 

Schiffer L, Barnard L, Baranowski ES, Gilligan LC, Taylor AE, Arlt W, et al. Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: A comprehensive review. J Steroid Biochem Mol Biol. 2019;194:105439.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl J Med. 2014;371:424–33.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl J Med. 2019;381:13–24.

CAS  PubMed  Article  Google Scholar 

Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl J Med. 2013;368:138–48.

CAS  PubMed  Article  Google Scholar 

de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl J Med. 2020;382:2091–102.

PubMed  Article  Google Scholar 

Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013;19:3621–30.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22:298–305.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell. 2017;32:474–89. e6.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017;355:84–8.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Boukovala M, Spetsieris N, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, et al. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer 2020;127:67–75.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Spetsieris N, Boukovala M, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, et al. A Phase 2 trial of abiraterone followed by randomization to addition of Dasatinib or Sunitinib in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2021;19:22–31. e5.

PubMed  Article  Google Scholar 

Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinforma. 2009;25:1754–60.

CAS  Article  Google Scholar 

DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43:491–8.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213–9.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinforma. 2009;25:2865–71.

CAS  Article  Google Scholar 

Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747–56.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014;346:256–9.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. 2004;5:557–72.

PubMed  Article  Google Scholar 

Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinforma. 2013;29:15–21.

CAS  Article  Google Scholar 

Anders S, Pyl PT, Huber W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinforma. 2015;31:166–9.

CAS  Article  Google Scholar 

Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, et al. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol. 2015;67:53–60.

CAS  PubMed  Article  Google Scholar 

Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30:637–43.

CAS  Article  Google Scholar 

Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res. 2005;11:4653–7.

CAS  PubMed  Article  Google Scholar 

Palanisamy N, Yang J, Shepherd PDA, Li-Ning-Tapia EM, Labanca E, Manyam GC, et al. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) captures the molecular landscape of prostate cancer and facilitates Marker-driven therapy development. Clin Cancer Res. 2020;26:4933–46.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Varkaris A, Corn PG, Parikh NU, Efstathiou E, Song JH, Lee YC, et al. Integrating Murine and clinical trials with Cabozantinib to understand roles of MET and VEGFR2 as targets for growth inhibition of prostate cancer. Clin Cancer Res. 2016;22:107–21.

CAS  PubMed  Article  Google Scholar 

Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013;155:1309–22.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, et al. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Hormones Cancer. 2014;5:72–89.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Missaghian E, Kempná P, Dick B, Hirsch A, Alikhani-Koupaei R, Jégou B, et al. Role of DNA methylation in the tissue-specific expression of the CYP17A1 gene for steroidogenesis in rodents. J Endocrinol. 2009;202:99–109.

CAS  PubMed  Article  Google Scholar 

Perkins LM, Payne AH. Quantification of P450scc, P450(17) alpha, and iron sulfur protein reductase in Leydig cells and adrenals of inbred strains of mice. Endocrinology 1988;123:2675–82.

CAS  PubMed  Article  Google Scholar 

Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA. 2019;116:11428–36.

留言 (0)

沒有登入
gif